Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Singulex is collaborating with Wyeth Research to develop immunoassays on the company's Erenna system that was installed at Wyeth as part of its Erenna technology access program.
Subscribe to our email newsletter
Singulex’s proprietary advanced biomarker detection technologies and optimized immunoassays are incorporated into Erenna, the company’s flagship biomarker detection platform system. Erenna and accompanying assays are designed to measure very low levels and small changes of protein biomarkers across a variety of biological samples from multiple species.
Singulex has begun optimizing assays that will allow Wyeth to accurately and precisely measure specific biomarkers in human blood.
Ole Vesterqvist, senior director of the biomarker laboratory in clinical translational medicine at Wyeth, said: “Singulex has provided us with a new technology for detection of biomarkers at very low concentrations and we are currently validating several assays in our laboratory that should help us guide our clinical programs.”